Summary
There are very few controlled trials of treatment of liver disease in either adults or children. This is unfortunate because there are considerable uncertainties surrounding the effectiveness of the treatments in use. However, controlled trials present considerable difficulties to investigators in terms of organization and maintenance of enthusiasm. In order to gain the maximum information from trials it is imperative to categorize patients accurately. The planning of the trial requires an infinite attention to detail. The plan should be as simple as is possible to answer the questions. It is important that controlled trials should be restricted to 2 years, duration wherever possible. This allows the investigator's interest to be maintained. In planning trials, it is important to remember that when the trial is mounted, the recruitment of patients is often considerably less than that which was expected. Because of the inadequacy of knowledge of effectiveness of treatment in liver disease it appears to be unethical to do anything other than controlled trials, henceforth. KRUGMAN (1972) in summarizing the 1971 Seminar on Viral Hepatitis held at the International Children's Centre, presented the six aspects of viral hepatitis which had been discussed. They included the clinical aspects, pathology, epidemiology, aetiology, immunology and prevention of hepatitis. There was no section on treatment. This is hardly surprising as until recently the effective treatments of hepatitis and indeed liver disease generally, have been relatively few. Controlled trials of drugs used to treat liver diseases are unusual. Chalmers (1968) suggested that there are 50 uncontrolled trials to every controlled one. Discussing the treatment of hepatic coma he stated that the number of trials which had been controlled could be measured on the fingers of one hand. Yet there are outstanding challenges for study of treatment in liver disease in childhood, such as chronic hepatitis, hepatic coma, progressive neonatal hepatitis and Reyes Syndrome. The reasons for little work on treatment of these conditions lie not only on the paucity of effective therapies, but also from the serious difficulties presented to the investigator. These include both the relative rarity of the problems and the uncertain outcome. Dr Porter et al.'s (1972) (Sutherland, 1972 (Hale, 1970) . Already this trial has shown a trend in favour of a particular treatment (streptokinase) but in order to get a statistically significant difference, the trial will need to continue for another 7 years and have an extra 1400 patients. On the other hand, those working on acute liver problems can gain strength and confidence from the recent Boston trial on only fifty-three patients which showed improved survival from acute renal failure after treatment with intravenous essential L amino acids and glucose compared with glucose alone (Abel et al., 1973) .
Another difficulty with multicentric trials is that once a trial has begun, for various reasons, the number of patients eligible for the entry into it diminishes to about a tenth of that which was predicted before the trial. There may be doubts about the diagnosis. (Thomson, 1972) . Medical progress in the right sense of the term can only be achieved if all the time we place the individual patient in the forefront. The question that every doctor must ask himself is, 'What will most benefit my patient?' I submit that whereas this is always the doctor's attitude, the very reason that a trial is being conducted means that the question is as yet unanswerable. The main ethical problem I see for trials of treatment in liver disease is whether it is ever justifiable not to do a controlled investigation using the best currently available treatment as the control.
